This Month in JNM ================= **PSMA PET in prostate cancer:** Jadvar provides perspective on prostate-specific membrane antigen as a biomarker in imaging evaluation of prostate cancer and previews a study on this topic in this issue of *JNM*. ***Page [1131](http://jnm.snmjournals.org/lookup/volpage/56/1131?iss=8)*** **Quantitative accuracy of PET/CT:** Kinahan and colleagues look at the increasing need for precision results in PET/CT assessment of tumor response to therapy and introduce a related article in this issue of *JNM*. ***Page [1133](http://jnm.snmjournals.org/lookup/volpage/56/1133?iss=8)*** **Imaging T cells:** Neri describes current efforts and challenges in imaging T cells in vivo and outlines the novel biomedical opportunities afforded by this capability. ***Page [1135](http://jnm.snmjournals.org/lookup/volpage/56/1135?iss=8)*** **PET/CT repeatability in NSCLC:** Weber and colleagues explore the repeatability of quantitative parameters derived from 18F-FDG PET/CT imaging in non–small cell lung cancer and discuss the application of these results in monitoring tumor response to therapy. ***Page [1137](http://jnm.snmjournals.org/lookup/volpage/56/1137?iss=8)*** **PET and tumor fluid penetrance:** Lubberink and colleagues assess the effects of imatinib and anakinra on perfusable tissue fraction and tumor blood flow in colorectal cancer metastases using 15O-water PET/CT and kinetic modeling. ***Page [1144](http://jnm.snmjournals.org/lookup/volpage/56/1144?iss=8)*** **Prognosis and pretherapeutic SUR:** Bütof and colleagues investigate whether 18F-FDG PET imaging can provide independent prognostic information in patients with inoperable esophageal carcinoma and whether the tumor-to-blood standard uptake ratio can enhance the quality of this information. ***Page [1150](http://jnm.snmjournals.org/lookup/volpage/56/1150?iss=8)*** **Intraarterial hepatic SPECT/CT:** Gates and colleagues demonstrate typical and atypical findings of 99mTc-MAA distribution on SPECT/CT obtained as part of pretherapeutic planning for radioembolization with 90Y microspheres. ***Page [1157](http://jnm.snmjournals.org/lookup/volpage/56/1157?iss=8)*** **PET/CT in pancreatic cysts:** Kauhanen and colleagues compare the accuracies of combined 18F-FDG PET and contrast-enhanced CT, multidetector CT, and MR imaging in differentiating malignant from benign pancreatic cysts. ***Page [1163](http://jnm.snmjournals.org/lookup/volpage/56/1163?iss=8)*** **68****Ga-/****177****Lu-PSMA theranostics:** Weineisen and colleagues describe development, preclinical evaluation, and proof-of-concept investigation of a prostate-specific membrane antigen inhibitor for imaging and therapy in patients with metastatic and castration-resistant prostate cancer. ***Page [1169](http://jnm.snmjournals.org/lookup/volpage/56/1169?iss=8)*** **PET/CT and survival after** **223****Ra:** Etchebehere and colleagues evaluate outcomes after 223Ra-diochloride therapy for hormone-refractory prostate cancer and determine whether skeletal tumor burden on whole-body 18F-fluoride PET/CT is prognostic for survival. ***Page [1177](http://jnm.snmjournals.org/lookup/volpage/56/1177?iss=8)*** **18****F-fluoromethylcholine vs.** **68****Ga-PSMA:** Morigi and colleagues compare the detection rates of a 68Ga-prostate-specific membrane antigen agent and 18F-fluoromethylcholine in PET/CT in men initially managed with radical prostatectomy, radiation treatment, or both who were being considered for targeted therapy. ***Page [1185](http://jnm.snmjournals.org/lookup/volpage/56/1185?iss=8)*** **PET/CT, MTV, and endometrial cancer:** Husby and colleagues explore the value of 18F-FDG PET/CT for preoperative staging in endometrial carcinomas and the correspondence of 18F-FDG PET–specific quantitative tumor parameters, including metabolic tumor volumes, to clinical and histologic characteristics. ***Page [1191](http://jnm.snmjournals.org/lookup/volpage/56/1191?iss=8)*** **PiB *R******1*** **as CBF proxy:** Chen and colleagues assess the suitability of 11C-Pittsburgh compound B blood–brain barrier delivery and relative delivery parameters as surrogate indices of cerebral blood flow in mild cognitive impairment and Alzheimer disease. ***Page [1199](http://jnm.snmjournals.org/lookup/volpage/56/1199?iss=8)*** **Red nucleus metabolic activity:** Hirata and colleagues use a high-resolution semiconductor PET system to investigate the metabolism of the human red nucleus and its correlation to other brain regions. ***Page [1206](http://jnm.snmjournals.org/lookup/volpage/56/1206?iss=8)*** **Current practices in V/Q scintigraphy:** Le Roux and colleagues survey current clinical standards of practice in Australia, Canada, and France for ventilation/perfusion imaging in evaluation of suspected acute pulmonary embolism. ***Page [1212](http://jnm.snmjournals.org/lookup/volpage/56/1212?iss=8)*** **Fetal** **18****F-FDG dosimetry:** Zanotti-Fregonara and colleagues estimate fetal radiation doses from 18F-FDG in a series of pregnant women who underwent PET imaging during clinical workup for malignancies. ***Page [1218](http://jnm.snmjournals.org/lookup/volpage/56/1218?iss=8)*** **Quantitative imaging of hypoxia:** Muzi and colleagues test the validity of using image-derived tissue regions that are highly correlated to blood levels as an alternative to serial blood sampling in 18F-FMISO PET assessment of hypoxia. ***Page [1223](http://jnm.snmjournals.org/lookup/volpage/56/1223?iss=8)*** **Upper gastrointestinal motility studies:** Maurer provides the first of 2 educational overviews of gastrointestinal scintigraphy, focusing here on esophageal transit and gastric emptying. ***Page [1229](http://jnm.snmjournals.org/lookup/volpage/56/1229?iss=8)*** **RIT with cetuximab in CRC:** Vassileva and colleagues evaluate the preclinical efficacy of combination radioimmunotherapy, using a humanized 131I-labeled anti-carcinoembryonic antigen antibody and cetuximab in colorectal cancer. ***Page [1239](http://jnm.snmjournals.org/lookup/volpage/56/1239?iss=8)*** **Imaging periostin for cancer invasion:** Heidari and colleagues develop and characterize a PET tracer that specifically targets the extracellular matrix protein periostin and evaluate this probe in preclinical models of esophageal squamous cell carcinoma. ***Page [1246](http://jnm.snmjournals.org/lookup/volpage/56/1246?iss=8)*** **TBI and** **64****CuCl****2** **PET/CT:** Peng and colleagues report on the potential of this copper-based PET imaging agent as a biomarker for experimental traumatic brain injury in mice. ***Page [1252](http://jnm.snmjournals.org/lookup/volpage/56/1252?iss=8)*** **Immuno-PET and T cell reconstitution:** Tavaré and colleagues detail the generation of anti-CD4 and -CD8 cys-diabodies derived from parental antibody hybridomas for 89Zr-immuno-PET detection of helper and cytotoxic T cell populations. ***Page [1258](http://jnm.snmjournals.org/lookup/volpage/56/1258?iss=8)*** **PET and tumor-associated macrophages:** Blykers and colleagues explore the identification and 18F-labeled antibody fragment PET assessment of M2-oriented tumor-supporting macrophages within the tumor microenvironment as indicators of cancer progression and prognosis. ***Page [1265](http://jnm.snmjournals.org/lookup/volpage/56/1265?iss=8)*** **89****Zr-HDL tumor-associated macrophage imaging:** Pérez-Medina and colleagues describe the development of reconstituted high-density lipoprotein-facilitated tumor-associated macrophage PET imaging in a preclinical breast cancer model. ***Page [1272](http://jnm.snmjournals.org/lookup/volpage/56/1272?iss=8)*** **PET/NIRF assessment of quantum dots:** Hu and colleagues report on a dual receptor–targeting dual-modality PET/near-infrared fluorescence probe for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of semiconductor quantum dots. ***Page [1278](http://jnm.snmjournals.org/lookup/volpage/56/1278?iss=8)*** **Isotopes, image quality, and hybrid scanners:** Soderlund and colleagues investigate image quality for 18F, 11C, 89Zr, 124I, 68Ga, and 90Y on PET/CT and PET/MR clinical scanners. ***Page [1285](http://jnm.snmjournals.org/lookup/volpage/56/1285?iss=8)*** * © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.